Literature DB >> 17208412

The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined.

Kelly J Skilbeck1, Jennifer N O'Reilly, Graham A R Johnston, Tina Hinton.   

Abstract

Changes in GABA(A) receptors are observed in schizophrenia, with benzodiazepine-sensitive GABA(A) receptor subtypes being affected differently to other subtypes. However, long-term antipsychotic drug use in schizophrenia may underlie these changes. To test this, we examined the effects of administering a typical (haloperidol) and an atypical (olanzapine) antipsychotic drug on the GABA(A) receptor agonist (orthosteric) and benzodiazepine (allosteric) binding sites in rat prefrontal cortex. As antipsychotic drugs have delayed maximal therapeutic effects we also examined different drug treatment periods. Male SD rats received a sucrose solution containing either haloperidol (1.5 mg/kg), olanzapine (6.5 mg/kg) or no drug daily for either 7, 14 or 28 days. Sections of rat brain were then labelled with [(3)H]muscimol, which labels the total population of GABA(A) receptors, or the benzodiazepine site ligand [(3)H]flunitrazepam in separate saturation binding experiments using quantitative receptor autoradiography. [(3)H]Muscimol binding was enhanced in the prefrontal cortex after 7 days but no differences were observed after longer periods of drug administration. In contrast there was a delayed increase in density of benzodiazepine-sensitive GABA(A) receptors in the PFC, suggesting that antipsychotic drugs have different effects on different GABA(A) receptor subtypes. These changes in the properties of GABA(A) receptor binding following antipsychotic drug administration are not consistent with those observed in schizophrenia and suggest a 'reshuffling' in GABA(A) receptor subtypes over time.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17208412     DOI: 10.1016/j.schres.2006.11.009

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Aripiprazole Increases the PKA Signalling and Expression of the GABAA Receptor and CREB1 in the Nucleus Accumbens of Rats.

Authors:  Bo Pan; Jiamei Lian; Xu-Feng Huang; Chao Deng
Journal:  J Mol Neurosci       Date:  2016-02-19       Impact factor: 3.444

2.  A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia.

Authors:  Meng di Hou; Viviana Santoro; Andrea Biondi; Sukhi S Shergill; Isabella Premoli
Journal:  J Psychiatry Neurosci       Date:  2021-12-21       Impact factor: 6.186

3.  Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats.

Authors:  Bo Pan; Xu-Feng Huang; Chao Deng
Journal:  Sci Rep       Date:  2016-07-20       Impact factor: 4.379

4.  GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.

Authors:  Elena Filatova; Anastasiya Kasian; Timur Kolomin; Ekaterina Rybalkina; Anelya Alieva; Lyudmila Andreeva; Svetlana Limborska; Nikolay Myasoedov; Galina Pavlova; Petr Slominsky; Maria Shadrina
Journal:  Front Pharmacol       Date:  2017-02-28       Impact factor: 5.810

5.  Tricyclic antipsychotics and antidepressants can inhibit α5-containing GABAA receptors by two distinct mechanisms.

Authors:  Konstantina Bampali; Filip Koniuszewski; Luca L Silva; Sabah Rehman; Florian D Vogel; Thomas Seidel; Petra Scholze; Florian Zirpel; Arthur Garon; Thierry Langer; Matthäus Willeit; Margot Ernst
Journal:  Br J Pharmacol       Date:  2022-03-07       Impact factor: 9.473

Review 6.  Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review.

Authors:  Fabrizio Schifano; Stefania Chiappini; John M Corkery; Amira Guirguis
Journal:  Brain Sci       Date:  2018-04-22

7.  Region-specific and dose-specific effects of chronic haloperidol exposure on [3H]-flumazenil and [3H]-Ro15-4513 GABAA receptor binding sites in the rat brain.

Authors:  Alba Peris-Yague; Amanda Kiemes; Diana Cash; Marie-Caroline Cotel; Nisha Singh; Anthony C Vernon; Gemma Modinos
Journal:  Eur Neuropsychopharmacol       Date:  2020-11-02       Impact factor: 4.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.